Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Rhea-AI Summary

NeOnc Technologies (NASDAQ: NTHI) received an initiation of coverage from Stonegate Capital Partners on January 9, 2026. NeOnc is a clinical-stage life sciences company developing central nervous system therapeutics that aim to overcome the blood-brain barrier, led by its proprietary compound NEO100.

Key program features include a patented synthesis for pharmaceutical-grade purity, an intranasal delivery strategy targeting olfactory and trigeminal pathways, reported favorable tolerability with prolonged dosing, and multiple near-term catalysts: positive Phase 1/2a results announced in December and a NEO100 Phase 2a top-line readout expected mid-2026. The announcement also notes that closing and funding of the Quazar Investment is expected in the near term.

Positive

• Stonegate Capital Partners initiated coverage on NTHI
• Positive Phase 1/2a results for NEO100 announced in December
• NEO100 Phase 2a top-line readout expected in mid-2026
• Intranasal delivery targets olfactory and trigeminal pathways for direct brain access

Negative

• Clinical-stage company dependent on a mid-2026 Phase 2a readout for near-term progress
• Advancement contingent on closing and funding of the Quazar Investment expected in the near term

News Market Reaction – NTHI

-3.50%

1 alert

-3.50% News Effect

-$7M Valuation Impact

$181M Market Cap

0.4x Rel. Volume

On the day this news was published, NTHI declined 3.50%, reflecting a moderate negative market reaction. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $181M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Phase 1/2a results: Phase 1/2a Phase 2a top-line: Phase 2a Readout timing: 2026 +1 more

4 metrics

Phase 1/2a results Phase 1/2a Positive NEO100 data referenced as a key takeaway

Phase 2a top-line Phase 2a Top-line readout for NEO100 expected mid-2026

Readout timing 2026 Program advances toward a 2026 readout per Stonegate note

Mid-2026 guidance Mid-2026 NEO100 Phase 2a top-line readout expected mid-2026

Market Reality Check

Price: $9.46 Vol: Volume 70,891 is modestly...

normal vol

$9.46 Last Close

Volume Volume 70,891 is modestly above the 65,171 20-day average, indicating slightly elevated interest ahead of this coverage note. normal

Technical Shares at $10.00 were trading above the $7.79 200-day moving average, reflecting an established uptrend before this coverage initiation.

Peers on Argus

While NTHI was up about 1.73%, key biotech peers like ELTX, IPHA, CCCC, KYTX, an...

While NTHI was up about 1.73%, key biotech peers like ELTX, IPHA, CCCC, KYTX, and TRDA were all down between roughly 2–6%, suggesting the move was stock-specific rather than sector-driven.

Historical Context

5 past events · Latest: Dec 15 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 15	Clinical update	Positive	-3.2%	Updated NEO100 data in 25‑patient cohort with remission and PFS signals.
Dec 01	Preclinical findings	Positive	-4.7%	AI‑driven work showing focused ultrasound enhances NEO100 antitumor potency.
Nov 14	Earnings & update	Neutral	-12.3%	Q3 2025 loss with Quazar deal, NIH grants, and NEO212/NEO100 pipeline progress.
Nov 13	Trial enrollment	Positive	-24.1%	Full enrollment in pivotal NEO100 Phase 2a and six‑month Q2 2026 readout guide.
Nov 12	Clinical update	Positive	+3.6%	Updated Phase 1/2a and compassionate‑use data with higher‑than‑benchmark efficacy.

Pattern Detected

Recent NEO100 and strategic updates have often been followed by negative or muted price reactions, even when clinical signals were positive.

Recent Company History

Over the last few months, NTHI has focused on advancing intranasal NEO100 for high‑grade glioma and strengthening its financial position. Clinical updates on Nov 12 and Dec 15, 2025 showed encouraging response and PFS data with favorable tolerability, yet shares declined after most of these releases. An $50.0 million Quazar strategic partnership and trial progress were highlighted in Q3 results, but that earnings update also saw a negative reaction. Today’s research coverage fits into a pattern of growing external validation around the NEO100 platform.

Market Pulse Summary

This announcement underscores third‑party research coverage of NeOnc’s intranasal NEO100 platform ta...

Analysis

This announcement underscores third‑party research coverage of NeOnc’s intranasal NEO100 platform targeting central nervous system tumors and emphasizing a potential 2026 Phase 2a readout and Quazar funding. In context, recent clinical updates reported favorable efficacy signals and tolerability, while SEC filings highlighted substantial losses and going‑concern language. Key factors to monitor include execution toward the mid‑2026 NEO100 data, progress on the Quazar investment, and any additional financing steps needed to support ongoing trials.

Key Terms

central nervous system, blood-brain barrier, intranasal administration, Phase 1/2a, +1 more

5 terms

central nervous system medical

"clinical-stage life sciences company developing central nervous system therapeutics"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

blood-brain barrier medical

"therapeutics designed to overcome the blood-brain barrier"

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.

intranasal administration medical

"NeOnc's intranasal administration strategy is designed to access the brain"

Intranasal administration is delivering a drug or vaccine through the nose so it is absorbed across the nasal lining into the body instead of being swallowed or injected. For investors, this matters because nose-delivered products can offer faster effects, easier use (no needles), and broader patient acceptance, which can reduce costs, simplify distribution and potentially expand market size compared with traditional oral or injectable options.

Phase 1/2a medical

"Key Takeaways: Positive Phase 1/2a results for NEO100 announced in December"

Phase 1/2a is an early stage in testing new medicines or treatments, combining two steps into one process. It helps researchers quickly assess whether a treatment is safe and shows signs of working, while also gathering initial information on the best dosage. For investors, this stage indicates how close a potential new therapy is to becoming available and its initial safety profile.

Phase 2a medical

"NEO100 Phase 2a top-line read out expected in Mid-2026"

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

AI-generated analysis. Not financial advice.

Dallas, Texas--(Newsfile Corp. - January 9, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners initiates their coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company developing central nervous system therapeutics designed to overcome the blood-brain barrier. The Company has numerous assets in its pipeline, highlighted by NEO100 which is a patented, pure pharmaceutical compound produced via proprietary synthesis for pharmaceutical-grade purity and reproducibility. NeOnc's intranasal administration strategy is designed to access the brain via olfactory and trigeminal pathways, offering a non-invasive route intended to improve adherence and enable more direct delivery. We view NTHI as a differentiated platform, supported by favorable tolerability with prolonged dosing and multiple near-term catalysts as the program advances toward a 2026 readout.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Positive Phase 1/2a results for NEO100 announced in December
• NEO100 Phase 2a top-line read out expected in Mid-2026
• Closing and funding of the Quazar Investment expected in the near-term

Click image above to view full announcement.

---

About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/279982

FAQ

What did Stonegate Capital Partners announce about NeOnc Technologies (NTHI) on January 9, 2026?

Stonegate initiated coverage on NTHI, highlighting the company’s CNS pipeline and the NEO100 program.

When is NEO100 Phase 2a top-line data for NTHI expected?

The NEO100 Phase 2a top-line readout is expected in mid-2026.

What clinical progress did NeOnc report for NEO100 prior to the Stonegate coverage?

NeOnc announced positive Phase 1/2a results for NEO100 in December.

How does NeOnc plan to deliver NEO100 to the brain for NTHI investors?

NeOnc uses an intranasal administration strategy intended to access the brain via olfactory and trigeminal pathways.

What funding event did the announcement mention that could affect NTHI?

The announcement said closing and funding of the Quazar Investment is expected in the near term.